Elite Pharmaceuticals, Inc.
ELTP
$0.53
$0.010.95%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.89M | 105.45M | 84.04M | 70.00M | 71.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.89M | 105.45M | 84.04M | 70.00M | 71.17M |
| Cost of Revenue | 58.18M | 46.61M | 43.96M | 39.09M | 39.34M |
| Gross Profit | 64.71M | 58.84M | 40.09M | 30.91M | 31.83M |
| SG&A Expenses | 12.42M | 10.66M | 9.23M | 9.43M | 8.40M |
| Depreciation & Amortization | 1.63M | 1.66M | 1.69M | 1.66M | 1.57M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.13M | 66.41M | 62.84M | 57.82M | 56.56M |
| Operating Income | 43.77M | 39.04M | 21.20M | 12.18M | 14.61M |
| Income Before Tax | 23.75M | -1.46M | -52.10K | -17.33M | -6.77M |
| Income Tax Expenses | 9.82M | 9.35M | 4.26M | 655.90K | -383.90K |
| Earnings from Continuing Operations | 13.92 | -10.82 | -4.31 | -17.99 | -6.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.92M | -10.82M | -4.31M | -17.99M | -6.39M |
| EBIT | 43.77M | 39.04M | 21.20M | 12.18M | 14.61M |
| EBITDA | 45.40M | 40.70M | 22.89M | 13.82M | 16.17M |
| EPS Basic | 0.01 | -0.01 | 0.00 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.01 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.01 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 4.28B | 4.27B | 4.27B | 4.22B | 4.17B |
| Average Diluted Shares Outstanding | 4.35B | 4.27B | 4.28B | 4.25B | 4.20B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |